Skip to main content
Top
Published in: Italian Journal of Pediatrics 1/2016

Open Access 01-12-2016 | Case report

Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report

Authors: Manuela Marsili, Valentina Marzetti, Marta Lucantoni, Giuseppe Lapergola, Marco Gattorno, Francesco Chiarelli, Luciana Breda

Published in: Italian Journal of Pediatrics | Issue 1/2016

Login to get access

Abstract

Background

Autoimmune sensorineural hearing loss, also known as autoimmune inner ear disease (AIED) is a rare clinical entity characterized by progressive and bilateral sensorineural hearing loss often accompanied by vestibular symptoms. Diagnosis is essential as a consistent number of patients show a positive response to steroids alone or in association with other immunosuppressive drugs. AIED is defined as primary when the disease is limited to the ear, whereas in up to a third of cases it is associated to other systemic autoimmune diseases such as Behçet disease (BD).
BD is a rare multisystem vasculitis characterized by recurrent oral and genital aphtosis, uveitis, skin lesions, neurological and vascular manifestations. Clinical presentation is variable thus making the diagnosis difficult in many instances. The choice of therapy is also limited by the scarceness of high-quality therapy studies.

Case presentation

We present a 15-year-old-boy with six months of history of fever, dizziness, tinnitus and ataxia. He had a final diagnosis of AIED associated to BD and was successfully treated with the anti-tumor necrosis factor (TNF)-α adalimumab.

Conclusions

This case report points out to the diagnostic and therapeutic challenges of BD especially when unusual symptoms are the prominent manifestations of the disease. It also suggests that adalimumab is a good therapeutic option in children with BD and audiovestibular symptoms.
Literature
1.
go back to reference Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the otology-rheumatology interface. Rheumatology. 2013;52:780–89.CrossRefPubMed Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the otology-rheumatology interface. Rheumatology. 2013;52:780–89.CrossRefPubMed
2.
go back to reference Ikiz AO, Unsal E, Kirkim G, Erdaq TK, Guneri EA. Hearing loss and middle ear involvement in patients with juvenile idiopathic arthritis. Int J Pediatr Otorinolaryngol. 2007;71:1079–85.CrossRef Ikiz AO, Unsal E, Kirkim G, Erdaq TK, Guneri EA. Hearing loss and middle ear involvement in patients with juvenile idiopathic arthritis. Int J Pediatr Otorinolaryngol. 2007;71:1079–85.CrossRef
3.
go back to reference International Team for the Revision of the International Criteria for Behçet's Disease (ITR- ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRef International Team for the Revision of the International Criteria for Behçet's Disease (ITR- ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRef
4.
go back to reference Alterburg A, Papoustis N, Orawa H, Martus P, Krause L, Zouboulis CC. Epidemiology and clinical manifestations of Adamantiades-Behcet disease in Germany-current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges. 2006;4(1):49–64.CrossRef Alterburg A, Papoustis N, Orawa H, Martus P, Krause L, Zouboulis CC. Epidemiology and clinical manifestations of Adamantiades-Behcet disease in Germany-current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges. 2006;4(1):49–64.CrossRef
6.
go back to reference Arber N, Klein T, Meiner Z, Pras E, Weinberger A. Close association of HLA-B51 and B52 in Israeli patients with Behçet's syndrome. Ann Rheum Dis. 1991;50:351–3.CrossRefPubMedPubMedCentral Arber N, Klein T, Meiner Z, Pras E, Weinberger A. Close association of HLA-B51 and B52 in Israeli patients with Behçet's syndrome. Ann Rheum Dis. 1991;50:351–3.CrossRefPubMedPubMedCentral
7.
go back to reference Morales-Angulo C, Vergara Pastrana S, Obeso-Agüera S, Acle L, González-Gay MÁ. Otorhinolaryngological manifestations in patients with Behçet disease. Acta Otorrinolaringol Esp. 2014;65:15–21.CrossRefPubMed Morales-Angulo C, Vergara Pastrana S, Obeso-Agüera S, Acle L, González-Gay MÁ. Otorhinolaryngological manifestations in patients with Behçet disease. Acta Otorrinolaringol Esp. 2014;65:15–21.CrossRefPubMed
8.
go back to reference International Study Group for Behçet's Disease. Criteria for diagnosis of Behcet Disease. Lancet. 1990;335:1078–80. International Study Group for Behçet's Disease. Criteria for diagnosis of Behcet Disease. Lancet. 1990;335:1078–80.
9.
go back to reference Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, et al. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2015 Dec;23 [Epub ahead of print]. Koné-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, et al. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2015 Dec;23 [Epub ahead of print].
10.
go back to reference Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behçet dysease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68(10):1528–34.CrossRefPubMed Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behçet dysease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68(10):1528–34.CrossRefPubMed
11.
go back to reference Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators Inflamm. 2002;11:87–93.CrossRefPubMedPubMedCentral Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators Inflamm. 2002;11:87–93.CrossRefPubMedPubMedCentral
12.
go back to reference Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–31.CrossRef Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–31.CrossRef
13.
go back to reference Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.CrossRefPubMed Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.CrossRefPubMed
Metadata
Title
Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report
Authors
Manuela Marsili
Valentina Marzetti
Marta Lucantoni
Giuseppe Lapergola
Marco Gattorno
Francesco Chiarelli
Luciana Breda
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2016
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-016-0291-2

Other articles of this Issue 1/2016

Italian Journal of Pediatrics 1/2016 Go to the issue